| Autor: |
D, Yakymenko, K B, Frandsen, I J, Christensen, A, Norgaard, P I, Johansson, G, Daugaard, M, Mau-Sorensen |
| Rok vydání: |
2016 |
| Předmět: |
|
| Zdroj: |
Transfusion medicine (Oxford, England). 28(3) |
| ISSN: |
1365-3148 |
| Popis: |
The primary objective of this feasibility study was to identify quality of life (QoL) scores and symptom scales as tools for measuring patient-reported outcomes (PRO) associated with haemoglobin level in chemotherapy-treated cancer patients. Secondary objectives included comparing QoL and symptoms between randomisation arms.Anaemia in cancer patients undergoing chemotherapy is associated with decreased QoL. One treatment option is red blood cell transfusion (RBCT). However, the optimal haemoglobin trigger for transfusion is unknown.Patients were randomised to a haemoglobin trigger for RBCT of either 9·7 g dLA total of 133 patients were enrolled, of which 86 patients received RBCT (28 in arm A, 58 in arm B). Baseline questionnaires were filled out in 79·7% of cases. Haemoglobin levels were significantly correlated with FACT-An, FACT-An Total Outcome Index (TOI), Functional Well-Being, fatigue and PS. Improvement on several PRO variables was observed in both arms after RBCT, with clinically minimal important differences observed in FACT-G, Physical Well-Being, FACT-An, FACT-An TOI, fatigue and dyspnoea.QoL scores of physical and functional domains as well as self-reported anaemia-related symptoms correlated well with haemoglobin level in chemotherapy-treated cancer patients. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text